S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NASDAQ:INCY

Incyte Stock Forecast, Price & News

$90.56
-1.48 (-1.61 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$89.32
Now: $90.56
$92.52
50-Day Range
$80.96
MA: $86.66
$94.31
52-Week Range
$62.48
Now: $90.56
$110.36
Volume930,173 shs
Average Volume978,539 shs
Market Capitalization$19.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.96
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Incyte logo

MarketRank

Overall MarketRank

1.86 out of 5 stars

Medical Sector

88th out of 1,558 stocks

Commercial Physical Research Industry

3rd out of 33 stocks

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:INCY
CUSIP45337C10
Phone302-498-6700
Employees1,456

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.16 billion
Cash Flow$2.44 per share
Book Value$12.06 per share

Profitability

Net Income$446.91 million

Miscellaneous

Market Cap$19.83 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$90.56
-1.48 (-1.61 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Incyte (NASDAQ:INCY) Frequently Asked Questions

How has Incyte's stock been impacted by Coronavirus (COVID-19)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INCY shares have increased by 26.0% and is now trading at $90.56.
View which stocks have been most impacted by COVID-19
.

Is Incyte a buy right now?

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 9 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Incyte stock.
View analyst ratings for Incyte
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Incyte?

Wall Street analysts have given Incyte a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Incyte wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Incyte
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) announced its earnings results on Thursday, November, 5th. The biopharmaceutical company reported $0.23 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.46 by $0.23. The biopharmaceutical company earned $620.64 million during the quarter, compared to analyst estimates of $622.48 million. Incyte had a negative net margin of 13.62% and a negative return on equity of 13.66%. The company's revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.82 earnings per share.
View Incyte's earnings history
.

What price target have analysts set for INCY?

21 Wall Street analysts have issued 12 month target prices for Incyte's stock. Their forecasts range from $86.00 to $124.00. On average, they expect Incyte's stock price to reach $103.56 in the next year. This suggests a possible upside of 14.4% from the stock's current price.
View analysts' price targets for Incyte
or view Wall Street analyst' top-rated stocks.

Who are some of Incyte's key competitors?

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Who are Incyte's key executives?

Incyte's management team includes the following people:
  • Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 61, Pay $2.47M)
  • Ms. Christiana Stamoulis, Exec. VP & CFO (Age 50, Pay $1.2M)
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 58, Pay $847.81k)
  • Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA, Exec. VP & GM of North America (Age 63, Pay $803.14k)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 54, Pay $937.73k)
  • Mr. Michael James Morrissey, Exec. VP & Head of Global Technical Operations (Age 57)
  • Dr. Dashyant Dhanak Ph.D., Exec. VP & Chief Scientific Officer (Age 60)
  • Mr. Michael Booth DPhil, Divisional VP of Investor Relations & Corp. Social Responsibility (Age 50)
  • Ms. Maria E. Pasquale, Exec. VP & Gen. Counsel (Age 55)
  • Ms. Pamela M. Murphy, VP of Investor Relations & Corp. Communications (Age 70)

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.01%), Louisiana State Employees Retirement System (0.01%), Crossmark Global Holdings Inc. (0.01%), IFM Investors Pty Ltd (0.01%) and NuWave Investment Management LLC (0.00%). Company insiders that own Incyte stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jean Jacques Bienaime, Jonathan Elliott Dickinson, Maria E Pasquale, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends for Incyte
.

Which institutional investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., State of Alaska Department of Revenue, and NuWave Investment Management LLC. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Paul Trower, Paula J Swain, Steven H Stein, and Yao Wenqing.
View insider buying and selling activity for Incyte
or view top insider-selling stocks.

Which institutional investors are buying Incyte stock?

INCY stock was acquired by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System, and IFM Investors Pty Ltd.
View insider buying and selling activity for Incyte
or or view top insider-buying stocks.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $90.56.

How big of a company is Incyte?

Incyte has a market capitalization of $19.83 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.